<a href="https://laohu8.com/S/BNTC">Benitec Biopharma</a> Inc. Reports No Revenue for Fiscal Year 2025; Net Loss Widens to $37.9 Million or $1.05 per Share
Benitec Biopharma Inc. has released its financial results for the year ended June 30, 2025. The company reported no revenues for both 2025 and the prior year. Total operating expenses for 2025 were $41.8 million, up from $22.5 million in 2024. Research and development expenses increased to $18.3 million from $15.6 million in the previous year, mainly due to the ongoing clinical development of BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). General and administrative expenses saw a significant rise to $23.4 million from $7.0 million, primarily due to an increase in share-based compensation and various other operational costs. The company reported a loss from operations amounting to $41.8 million in 2025, compared to a loss of $22.5 million in 2024. Net loss attributable to shareholders was $37.9 million, compared to a net loss of $22.4 million in the previous year. As of June 30, 2025, Benitec Biopharma had $97.7 million in cash and cash equivalents. The company anticipates providing additional clinical study results for Cohort 1 Subjects in the fourth calendar quarter of this year.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-211462), on September 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.